Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 189 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Uveal Melanoma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Uveal Melanoma, Liver Metastases
Interventions
GM-CSF, Embolization
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Uveal Melanoma
Interventions
Quisinostat
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Metastatic Uveal Melanoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Jose Lutzky, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Uveal Melanoma
Interventions
PAC-1, Entrectinib
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye Cancer
Interventions
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
Drug
Lead sponsor
Novelwise Pharmaceutical Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Melanoma
Interventions
Cyclophosphamide, Fludarabine, Interleukin-2, TIL Product
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IV Uveal Melanoma
Interventions
Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Selumetinib, Temozolomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
32
States / cities
Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced May 21, 2026, 6:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Interventions
Not listed
Lead sponsor
Mohamed Abdel-Rahman
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pyrazoloacridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Interventions
gp100 antigen, interleukin-2, MART-1 antigen, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Uveal Melanoma, Radiation Retinopathy, Radiation Maculopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Shields, Shields and Associates
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2007 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Uveal Melanoma
Interventions
Selumetinib, 100mg, Selumetinib, 125mg, Selumetinib, 150mg, Selumetinib, 175mg, Selumetinib, 200mg, Selumetinib, 225mg
Drug
Lead sponsor
Shaheer A. Khan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma
Interventions
Pembrolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
Interventions
Melphalan, Percutaneous Hepatic Perfusion
Drug · Device
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
U.S. locations
6
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Metastatic Uveal Melanoma
Interventions
Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 21, 2026, 6:44 PM EDT
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced May 21, 2026, 6:44 PM EDT
Completed Phase 2 Interventional Results available
Conditions
Melanoma
Interventions
Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced May 21, 2026, 6:44 PM EDT